The radiotherapy treatment comes from an electrical machine called a ‘Linear accelerator’ and is directed as a beam to the part of the body that needs to be treated. Treatment is given daily over a period of days or weeks and you may hear people call these treatments ‘fractions’. They are just a fraction of your treatment dose and plan.
Immunotherapy is a biological therapy and type of targeted treatment that boosts the patient’s natural defence, the immune system, and enables it to find and destroy cancer cells found in the body. At Rutherford Cancer Centres, we use several different types of immunotherapy in the treatment of cancer, in order to prevent cells growing and replicating or spreading around the body.
Chemotherapy at the Rutherford takes place in our modern therapy suites, consisting of up to ten treatment areas offering treatment for haematology/oncology patients requiring systemic anti-cancer therapy (SACT) and supportive care in an outpatient setting. The infusion therapy suites are available for patients undergoing treatment for breast, urology, upper and lower gastrointestinal cancers, and both malignant and non-malignant haematology disorders.
Dr Shaw trained at Liverpool University Medical School and during this time received Medical Research Council funding to complete an intercalated Physiology degree. His general medical training in Bristol (Frenchay Hospital) lead him to work at the Royal Marsden Hospital and his interest in oncology.
He is dual trained in Clinical Oncology and Palliative Medicine (Oxford) with over 20 years experience of NHS care. His work based at Velindre Cancer Centre includes both the radical and palliative managements of patients with lung, oesophago-gastric and anal cancers. He is active in recruitment to clinical trials including local lead investigator roles for national lung (Matrix), anal cancer (Plato) and commercial trials. He is also the lead Clinical Oncologist for Early Phase Drug Radiation studies at Velindre Cancer Centre and is a Co-investigator for the developing UK Non-Small Cell Lung cancer study to test DNA damage and repair pathway inhibitors with radiation.
Dr Shaw combines full time NHS practice with academic responsibilities within the School of Bioscience, where he is an Honorary Senior Lecturer at Cardiff University. He completed PhD studies funded by the Cancer Research UK Bobby Moore Clinical Research Fellowship in Prof Alan Clarke’s laboratory (PhD awarded 2010). Since then he has Co-Supervised 3 PhD students at Cardiff University and has secured further funding to develop a lung cancer model with Oxford University to test drugs and radiotherapy combinations (PhD 2018-2021, Cancer Research Wales).
His complimentary NHS/Academic roles include being Co-chair of the Wales Cancer Partnership Lung Multi-Disciplinary Research Group, which aims to promote research collaborations across Wales. He is also a member of the Radiation Research Group at Velindre Cancer Centre and senior committee representative of the Cardiff Experimental Cancer Medicine Centre and member of CTrad science work stream.
Outside of work Dr Shaw likes to pursue an active lifestyle and is a very keen cyclist and loves nothing better than battling his way up some of the beautiful Welsh valleys on two wheels. He is happily married and loves living in Wales.
Fellow of the Royal College of Radiologists
Member of the Royal College of Physicians
CTRad science workstream committee member
Senior team member Cardiff ECMC
Dr Paul Shaw does not hold a share or financial interest in the Rutherford Cancer Centres or another Proton Partners International company.
Dr Paul Shaw does not have a share or financial interest in equipment used at the Rutherford Cancer Centres or another Proton Partners International company.
Dr Paul Shaw does not hold any paid advisory role(s) at the Rutherford Cancer Centres or on behalf of Rutherford Cancer Centres or Proton Partners International.